Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis

Enhancement of glial-derived neurotrophic factor (GDNF) is an established therapeutic target for amyotrophic lateral sclerosis (ALS). Activation of group II metabotropic glutamate (mGlu) receptors with the orthosteric agonist, LY379268, enhanced GDNF levels in cultured spinal cord astrocytes from wild-type mice and mGlu2(-/-) mice, but not in astrocytes from mGlu3(-/-) mice. LY379268 protected Sternberger monoclonal incorporated antibody-32 (SMI-32)(+) motor neurons against excitotoxic death in mixed cultures of spinal cord cells, and its action was abrogated by anti-GDNF antibodies. Acute systemic injection of LY379268 (0.5, 1 or 5mg/kg, i.p.) enhanced spinal cord GDNF levels in wild-type and mGlu2(-/-) mice, but not in mGlu3(-/-) mice. No tolerance developed to the GDNF-enhancing effect of LY379268 when the drug was continuously delivered for 28days by means of s.c. osmotic minipumps (0.5-5mg/day). Double fluorescent immunostaining showed a co-localization of GDNF with the astrocyte marker, GFAP, but not with the neuronal marker, Neuronal Nuclear Antigen (NeuN), or with SMI-32. Continuous infusion of LY379268 also enhanced the expression of the glutamate transporter GLT-1, in the spinal cord. These data laid the groundwork for the study of LY379268 in ALS mice. Continuous treatment with 1 or 5mg/kg/day with LY379268 had a beneficial effect on neurological disability in SOD1G93A mice. At day 40 of treatment, LY379268 enhanced spinal cord levels of GDNF and GLT-1, and rescued spinal cord motor neurons, as assessed by stereologic counting of SMI-32(+) cells. LY379268 had no significant effect on the mortality rate of SODG93A. These findings encourage the development of selective mGlu3 receptor agonists/enhancers as neuroprotective agents in ALS.

[1]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[2]  J. Rothstein,et al.  Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex , 1996, Annals of neurology.

[3]  D. Schoepp,et al.  Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine , 2000, Psychopharmacology.

[4]  S. Minotti,et al.  Optimized protocols for isolation of primary motor neurons, astrocytes and microglia from embryonic mouse spinal cord , 2007, Journal of Neuroscience Methods.

[5]  David S Wishart,et al.  Intermolecular transmission of superoxide dismutase 1 misfolding in living cells , 2011, Proceedings of the National Academy of Sciences.

[6]  Jeffery N Agar,et al.  Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS , 2010, Nature Neuroscience.

[7]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[8]  M. Swash,et al.  Controversies and priorities in amyotrophic lateral sclerosis , 2013, The Lancet Neurology.

[9]  A. Schousboe,et al.  The high-affinity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via different signalling mechanisms , 2000, Neurochemistry International.

[10]  C. Donadoni,et al.  Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. , 2004, Brain : a journal of neurology.

[11]  E. Aronica,et al.  Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes , 2001, Neuroscience.

[12]  J. Rothstein,et al.  Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS) , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Hu,et al.  Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes , 2005, Journal of neurochemistry.

[14]  V. Meininger,et al.  A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis , 2002, Journal of Neurology.

[15]  David M. Bodine,et al.  Bone marrow cells regenerate infarcted myocardium , 2001, Nature.

[16]  J. Grutsch,et al.  Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. , 1999, Journal of medicinal chemistry.

[17]  P. Pennefather,et al.  Group I and II metabotropic glutamate receptor expression in cultured rat spinal cord astrocytes , 1999, Neuroscience Letters.

[18]  F. Nicoletti,et al.  Molecular Signalling Mediating the Protective Effect of A1 Adenosine and mGlu3 Metabotropic Glutamate Receptor Activation against Apoptosis by Oxygen/Glucose Deprivation in Cultured Astrocytes , 2007, Molecular Pharmacology.

[19]  E. Nisenbaum,et al.  Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective , 2011, Molecular Pharmacology.

[20]  O. Isacson,et al.  Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection. , 2010, Brain : a journal of neurology.

[21]  H. Mizukami,et al.  Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis , 2002, The Journal of Neuroscience.

[22]  M. Lasaga,et al.  Reduced cAMP, Akt Activation and p65-c-Rel Dimerization: Mechanisms Involved in the Protective Effects of mGluR3 Agonists in Cultured Astrocytes , 2011, PloS one.

[23]  A. Guidotti,et al.  Pharmacological Activation of Group-II Metabotropic Glutamate Receptors Corrects a Schizophrenia-Like Phenotype Induced by Prenatal Stress in Mice , 2012, Neuropsychopharmacology.

[24]  M. Lasaga,et al.  Metabotropic glutamate receptor 3 activation prevents nitric oxide‐induced death in cultured rat astrocytes , 2010, Journal of neurochemistry.

[25]  C. Svendsen,et al.  GDNF Secreting Human Neural Progenitor Cells Protect Dying Motor Neurons, but Not Their Projection to Muscle, in a Rat Model of Familial ALS , 2007, PloS one.

[26]  M. Chen,et al.  Glutamate-Dependent Neuroglial Calcium Signaling Differs Between Young and Adult Brain , 2013, Science.

[27]  F. Nicoletti,et al.  The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3 Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection , 2007, The Journal of Neuroscience.

[28]  A. Levey,et al.  Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis , 1995, Annals of neurology.

[29]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[30]  H J Gundersen,et al.  The efficiency of systematic sampling in stereology and its prediction * , 1987, Journal of microscopy.

[31]  M. Saarma,et al.  GDNF family receptor complexes are emerging drug targets. , 2007, Trends in pharmacological sciences.

[32]  D. Schoepp.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. , 2001, The Journal of pharmacology and experimental therapeutics.

[33]  F. Nicoletti,et al.  Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.

[34]  F. Nicoletti,et al.  A prolonged pharmacological blockade of type-5 metabotropic glutamate receptors protects cultured spinal cord motor neurons against excitotoxic death , 2011, Neurobiology of Disease.

[35]  F. Nicoletti,et al.  Activation of A1 adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S‐100β protein from cultured astrocytes , 1999, Glia.

[36]  H. Kimelberg,et al.  mGluR3 and mGluR5 are the predominant metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats , 1999, Journal of neuroscience research.

[37]  A. Calas,et al.  Opposite regulation of metabotropic glutamate receptor 3 and metabotropic glutamate receptor 5 by inflammatory stimuli in cultured microglia and astrocytes , 2012, Neuroscience.

[38]  S. Russo,et al.  Prenatal Stress Induces Schizophrenia-Like Alterations of Serotonin 2A and Metabotropic Glutamate 2 Receptors in the Adult Offspring: Role of Maternal Immune System , 2013, The Journal of Neuroscience.

[39]  N. Maragakis,et al.  Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo , 2011, Proceedings of the National Academy of Sciences.

[40]  E. Aronica,et al.  Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins , 2003, The European journal of neuroscience.

[41]  M. Entman,et al.  Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. , 2001, The Journal of clinical investigation.

[42]  P. Bosco,et al.  TGF‐β1 Pathway as a New Target for Neuroprotection in Alzheimer's Disease , 2011, CNS neuroscience & therapeutics.

[43]  D. Schoepp,et al.  Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice , 2005, Psychopharmacology.

[44]  N. Belluardo,et al.  Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons , 2009, PloS one.

[45]  C. Svendsen,et al.  Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[47]  A. Pittaluga,et al.  Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis , 2013, Neuropharmacology.

[48]  M. C. Bohn,et al.  Motoneurons crave glial cell line-derived neurotrophic factor , 2004, Experimental Neurology.

[49]  P. Anversa,et al.  Evidence that human cardiac myocytes divide after myocardial infarction. , 2001, The New England journal of medicine.

[50]  C. Corti,et al.  The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity , 2008, Psychopharmacology.

[51]  C. Henderson,et al.  GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. , 1994, Science.

[52]  C. Swanson,et al.  The Group II Metabotropic Glutamate Receptor Agonist (−)-2-Oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and Clozapine Reverse Phencyclidine-Induced Behaviors in Monoamine-Depleted Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.

[53]  Michael A King,et al.  Particle detection, number estimation, and feature measurement in gene transfer studies: optical fractionator stereology integrated with digital image processing and analysis. , 2002, Methods.

[54]  E. Hermans,et al.  Differential regulation of the glutamate transporter variants GLT-1a and GLT-1b in the cortex and spinal cord of transgenic rats expressing hSOD1G93A , 2013, Neurochemistry International.

[55]  A. Volterra,et al.  Focal degeneration of astrocytes in amyotrophic lateral sclerosis , 2008, Cell Death and Differentiation.

[56]  E. Aronica,et al.  The BH4 domain of Bcl-X(L) rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. , 2012, Human molecular genetics.

[57]  D. Choi,et al.  Glutamate neurotoxicity in spinal cord cell culture , 1991, Neuroscience.

[58]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[59]  F. Nicoletti,et al.  The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.

[60]  S. Nakanishi,et al.  Structural organization of the mouse metabotropic glutamate receptor subtype 3 gene and its regulation by growth factors in cultured cortical astrocytes. , 1999, Journal of biochemistry.

[61]  Erwin Hauser,et al.  Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice , 1999, Anatomy and Embryology.

[62]  G. Borasio,et al.  Differential expression of mGluR5 in human lumbosacral motoneurons , 2004, Neuroreport.